Duncan Mackintosh

Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.

Graftoss Ltd. develops orthopedic devices which have bone graft and bone replacement applications. The firm's bone matrix technology has applications as a xenograft material for human and veterinary grafting, including spinal fusion, hand and foot surgery, simple and complex fractures repair, joint reconstruction and dental implants and as an antibiotic impregnated graft material for application in conditions such as osteomyelitis. The company was founded in 2007 and is headquartered in Hamilton, New Zealand.

OBodies Ltd. engages in the research and development of affinity proteins. It offers antibody-like biopharmaceuticals derived from proteins. The firm's platform technology has applications within clinical diagnostics, point of care diagnostics, biotechnology research, industrial biotechnology, and medical therapeutics. The company was founded in 2007 and is headquartered in Hamilton, New Zealand.